Compare AU
Compare XMET vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Energy Transition Metals ETF (XMET) and the BetaShares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
XMET | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 29 | 61 |
Median incremental investment | $1,007.50 | $920.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $983.40 | $1,892.10 |
Average age group | > 35 | 26 - 35 |
Key Summary
XMET | DRUG | |
|---|---|---|
Strategy | XMET.AX was created on 2022-10-26 by BetaShares. The fund's investment portfolio concentrates primarily on materials equity. The investment objective of the Fund is to provide an investment return that aims to track the performance of the Nasdaq Sprott Energy Transition Materials Select Index, before taking into account fees and expenses | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | FIRST QUANTUM MINERALS LTD (6.03 %) WHEATON PRECIOUS METALS CORP (5.85 %) SOUTHERN COPPER CORP (5.64 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (65.48 %) Materials (34.38 %) Information Technology (0.14 %) | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) |
Top 3 countries | Canada (36.79 %) Australia (17.96 %) United States (17.25 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.69 % | 0.57 % |
Key Summary
XMET | DRUG | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Sprott Energy Transition Materials Select Index - AUD - Benchmark TR Net | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.69 % | 0.57 % |
Price | $7.45 | $7.95 |
Size | $22.545 million | $185.172 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.37 % | 1.90 % |
Market | ASX | ASX |
First listed date | 27/10/2022 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
XMET | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 29 | 61 |
Median incremental investment | $1,007.50 | $920.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $983.40 | $1,892.10 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
XMET | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
XMET | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |